Valmet DNA Local privilege escalation through insecure DCOM configuration

published 2025-04-01 last yr. modified 2026-08-26 2mo ago also EUVD-2025-9126

cvss: 8.9; version 4.0, CNA
cisa kev: Not listed; not in CISA's catalog
epss: 0.2%; EPSS 0.2% chance of exploitation in 30 days, percentile 11%
public exploits: 0; none known

Local privilege escalation through insecure DCOM configuration in Valmet DNA versions prior to C2023. The DCOM object Valmet DNA Engineering has permissions that allow it to run commands as a user with the SeImpersonatePrivilege privilege. The SeImpersonatePrivilege privilege is a Windows permission that allows a process to impersonate another user. An attacker can use this vulnerability to escalate their privileges and take complete control of the system.

Is CVE-2025-0416 in your stack? Fencer shows which of your repositories are affected as soon as an advisory lands, and opens the fix as a pull request.

Check with Fencer

CISA SSVC

Exploitation: none
Automatable: no
Technical impact: total
Assessed: last yr. (2025-04-01)

Exploit prediction

0.21% chance of exploitation in the next 30 days, higher than 11% of all scored CVEs (FIRST EPSS, 2026-11-11).

CVSS scores

assigned by	version	score	vector
CNA	4.0	8.9	CVSS:4.0/AV:A/AC:L/AT:P/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/S:N/AU:Y/R:U/V:D/RE:H/U:Amber
CNA	4.0	8.9	CVSS:4.0/AV:A/AC:L/AT:P/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:N/AU:Y/R:U/V:D/RE:H/U:Amber

Affected products

Valmet Valmet DNA

Classification

Weakness

CWE-250 Execution with Unnecessary Privileges

References

valmet.com /about-us/about/research-and-development/vulnerabilityadvisories/cve-2025-0416/

Sources

CVE List CVE-2025-0416
NVD CVE-2025-0416

Fencer Intel keeps one entry per vulnerability: the CVE id wins, then GHSA, and records that alias each other are merged, except that two CVEs always keep separate entries. The same data is available as JSON.